These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 37376478)

  • 1. Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion.
    Postma M; Fisman D; Giglio N; Márquez-Peláez S; Nguyen VH; Pugliese A; Ruiz-Aragón J; Urueña A; Mould-Quevedo J
    Vaccines (Basel); 2023 Jun; 11(6):. PubMed ID: 37376478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective - A systematic review of recently published literature on real-world data.
    Gärtner BC; Weinke T; Wahle K; Kwetkat A; Beier D; Schmidt KJ; Schwarz TF
    Vaccine; 2022 May; 40(22):2999-3008. PubMed ID: 35459556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany.
    Kohli MA; Maschio M; Cartier S; Mould-Quevedo J; Fricke FU
    Vaccines (Basel); 2022 Aug; 10(9):. PubMed ID: 36146464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom.
    Kohli MA; Maschio M; Mould-Quevedo JF; Drummond M; Weinstein MC
    Hum Vaccin Immunother; 2021 Nov; 17(11):4603-4610. PubMed ID: 34550848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly.
    Mullikin M; Tan L; Jansen JP; Van Ranst M; Farkas N; Petri E
    Infect Dis Ther; 2015 Dec; 4(4):459-87. PubMed ID: 26350238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017-2018 Influenza Season.
    Pelton SI; Divino V; Shah D; Mould-Quevedo J; DeKoven M; Krishnarajah G; Postma MJ
    Vaccines (Basel); 2020 Aug; 8(3):. PubMed ID: 32784684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta-analysis.
    Coleman BL; Sanderson R; Haag MDM; McGovern I
    Influenza Other Respir Viruses; 2021 Nov; 15(6):813-823. PubMed ID: 34081398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population.
    Fochesato A; Sottile S; Pugliese A; Márquez-Peláez S; Toro-Diaz H; Gani R; Alvarez P; Ruiz-Aragón J
    Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Vaccination of Older Adults with an MF59
    Jacob J; Biering-Sørensen T; Holger Ehlers L; Edwards CH; Mohn KG; Nilsson A; Hjelmgren J; Ma W; Sharma Y; Ciglia E; Mould-Quevedo J
    Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of high dose versus adjuvanted trivalent influenza vaccines in England and Wales.
    Mattock R; Gibbons I; Moss J; Mealing S; Largeron N; Carroll S; Alvarez FP
    J Med Econ; 2021; 24(1):1261-1271. PubMed ID: 34726129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine versus standard and alternate B strain MF59-adjuvanted trivalent influenza vaccines in older adults.
    Essink B; Fierro C; Rosen J; Figueroa AL; Zhang B; Verhoeven C; Edelman J; Smolenov I
    Vaccine; 2020 Jan; 38(2):242-250. PubMed ID: 31635976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain.
    Ruiz-Aragón J; Márquez-Peláez S; Gani R; Alvarez P; Guerrero-Luduena R
    Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain.
    Ruiz-Aragón J; Márquez-Peláez S
    Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective cohort study assessing relative effectiveness of adjuvanted versus high-dose trivalent influenza vaccines among older adults in the United States during the 2018-19 influenza season.
    Pelton SI; Divino V; Postma MJ; Shah D; Mould-Quevedo J; DeKoven M; Krishnarajah G
    Vaccine; 2021 Apr; 39(17):2396-2407. PubMed ID: 33810903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The New Quadrivalent Adjuvanted Influenza Vaccine for the Italian Elderly: A Health Technology Assessment.
    Calabrò GE; Boccalini S; Panatto D; Rizzo C; Di Pietro ML; Abreha FM; Ajelli M; Amicizia D; Bechini A; Giacchetta I; Lai PL; Merler S; Primieri C; Trentini F; Violi S; Bonanni P; de Waure C
    Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Influenza Vaccination Strategies in Adults: Older Adults Aged ≥65 Years, Adults Aged 50-64 Years, and At-Risk Adults Aged 19-64 Years.
    Choi MJ; Shin G; Kang D; Lim JO; Kim YK; Choi WS; Yun JW; Noh JY; Song JY; Kim WJ; Choi SE; Cheong HJ
    Vaccines (Basel); 2022 Mar; 10(3):. PubMed ID: 35335077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic Review on the Cost-Effectiveness of Seasonal Influenza Vaccines in Older Adults.
    Loong D; Pham B; Amiri M; Saunders H; Mishra S; Radhakrishnan A; Rodrigues M; Yeung MW; Muller MP; Straus SE; Tricco AC; Isaranuwatchai W
    Value Health; 2022 Aug; 25(8):1439-1458. PubMed ID: 35659487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of influenza vaccine strategies for the elderly in South Korea.
    Yun JW; Choi MJ; Shin GS; Lim JO; Noh JY; Kim YK; Song JY; Kim WJ; Choi SE; Cheong HJ
    PLoS One; 2019; 14(1):e0209643. PubMed ID: 30682030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated exposure to an MF-59 adjuvanted quadrivalent subunit influenza vaccine (aQIV) in children: Results of two revaccination studies.
    Vesikari T; Ramsey K; Pitisuttithum P; Capeding R; Heijnen E; Sawlwin D; Oberyé J; Zhang B; Smolenov I
    Vaccine; 2020 Dec; 38(51):8224-8231. PubMed ID: 33139136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of the adjuvanted quadrivalent influenza vaccine in the elderly Belgian population.
    Marbaix S; Dauby N; Mould-Quevedo J
    Expert Rev Vaccines; 2023; 22(1):608-619. PubMed ID: 37368472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.